Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

A Phase IIa Study of Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab in Patients with Asymptomatic Brain Metastasis from Triple Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC)

Principal Investigator: Gandhi, Shipra

Photoacoustic Imaging of Human Breast

Principal Investigator: Bonaccio, Ermelinda

PrE0113:A study to assess overall response rate by inducing an inflammatory phenotype in Metastatic BReast cAnCEr with the Oncolytic Reovirus PeLareorEp in CombinaTion with anti-PD-L1 Avelumab and Paclitaxel BRACELET-1 Study

Principal Investigator: Levine, Ellis G

Exercise to Improve Health and Quality-of-life in Breast Cancer Survivors: A Feasibility Pilot Trial

Principal Investigator: O'Connor, Tracey L

A Multicenter Phase II Study of Vaccines to Prevent Recurrence in Patients with HER-2 Positive Breast Cancer

Principal Investigator: Gandhi, Shipra

(S1706) A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer

Principal Investigator: Fung-Kee-Fung, Simon

EA1181 (CompassHER2 pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response

Principal Investigator: Levine, Ellis G

(A011801) The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with…

Principal Investigator: Levine, Ellis G

NRG-BR007: A PHASE III CLINICAL TRIAL EVALUATING DE-ESCALATION OF BREAST RADIATION FOR CONSERVATIVE TREATMENT OF STAGE I, HORMONE SENSITIVE, HER2-NEGATIVE, ONCOTYPE RECURRENCE SCORE ≤ 18 BREAST CANCER

Principal Investigator: Fung-Kee-Fung, Simon